Deferred Tax Assets, Operating Loss Carryforwards in USD of Nurix Therapeutics, Inc. from Q4 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Nurix Therapeutics, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and change rate from Q4 2019 to Q4 2024.
  • Nurix Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 30 Nov 2024 was $91,786,000, a 0.37% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Nurix Therapeutics, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $91,786,000 -$345,000 -0.37% 30 Nov 2024 10-K 28 Jan 2025 2024 FY
Q4 2023 $92,131,000 +$8,356,000 +10% 30 Nov 2023 10-K 28 Jan 2025 2024 FY
Q4 2022 $83,775,000 +$42,694,000 +104% 30 Nov 2022 10-K 15 Feb 2024 2023 FY
Q4 2021 $41,081,000 +$15,936,000 +63% 30 Nov 2021 10-K 09 Feb 2023 2022 FY
Q4 2020 $25,145,000 -$6,388,000 -20% 30 Nov 2020 10-K 28 Jan 2022 2021 FY
Q4 2019 $31,533,000 30 Nov 2019 10-K 16 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.